Test Price
2,800 AED✅ Home Collection Available
RAD51C Gene Mutation Analysis (Hereditary Breast & Ovarian Cancer) – Next‑Generation Sequencing in UAE | 2,800 AED | 2026 DHA Guidelines
تحليل طفرة جين RAD51C لسرطان الثدي والمبيض في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
- Accuracy Guarantee
- 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics
- Paid Hospital‑Grade Home Collection via ISO Certified Cold‑Chain Home Collection & VIP Mobile Phlebotomy.
- Clinical Guidance
- Telephonic Post‑Test Clinical Guidance for Result Interpretation – discuss findings with DHA‑licensed oncologists and genetic counsellors.
- Insurance
- Direct Billing Verification via WhatsApp +971 54 548 8731.
الملخص التنفيذي: اختبار جين RAD51C باستخدام تقنية التسلسل الجيني من الجيل التالي يوفر دقة تشخيصية استثنائية بنسبة 99.9%، مع خدمة جمع عينات منزلية عالية الجودة، وإرشاد طبي هاتفي بعد النتيجة، والتزام كامل بالقوانين الاتحادية لدولة الإمارات العربية المتحدة.
Overview
RAD51C Gene Mutation Analysis is a clinically validated Next‑Generation Sequencing (NGS) test that detects germline mutations in the RAD51C gene, a key player in hereditary breast and ovarian cancer syndrome. This 2,800 AED investigation, performed under 2026 DHA guidelines, empowers high‑risk individuals and their physicians to make proactive, personalised screening and prevention decisions.
تحليل طفرة جين RAD51C هو فحص جيني متطور يكشف الطفرات الوراثية المرتبطة بمتلازمة سرطان الثدي والمبيض الوراثي، مما يتيح اتخاذ قرارات استباقية للفحص والوقاية.
| Feature | RAD51C UAE Power Test | Standard Local Genetic Panel |
|---|---|---|
| Precision | 99.9% Sensitivity – full‑gene sequencing with CNV detection (NGS + MLPA backup) | Often limited to hotspot analysis; may miss large deletions |
| Methodology | Illumina‑based NGS, ACMG 2026 variant interpretation, Sanger confirmation | Older PCR‑based genotyping or basic Sanger sequencing |
| Turnaround & Support | 3–4 Weeks · Home Collection 8 AM–11 PM · Post‑test tele‑guidance | Often ≥6 Weeks · In‑clinic draw only · Minimal post‑test follow‑up |
Physician Insight & Safety Protocol
Dr. PRABHAKAR REDDY (DHA Licence: 61713011) : “As an oncologist with deep expertise in hereditary cancers, I emphasise that RAD51C results must always be interpreted alongside full family history. A positive variant does not alone dictate your cancer fate, but it empowers you and your care team to implement life‑saving surveillance or prophylactic measures. Always discuss your results with a qualified genetic counsellor before making any medical decision.”
Medication & Lifestyle Warning
Do not discontinue prescribed medication (e.g., oral contraceptives, hormonal therapies) or modify screening schedules without consulting your managing physician. This genetic test provides risk information, not a clinical diagnosis, and must be integrated with ongoing specialist care.
Safety Exclusion Criteria & ER Red Flags
- Exclusion Criteria: Individuals under 18 without court‑appointed legal guardian consent (CDS Law 2026, Minors); inability to give informed consent (e.g., acute psychiatric crisis); sample contamination or insufficient DNA yield.
- Red Flags – Seek Emergency Help if you experience: severe anxiety, panic attacks, or suicidal ideation after receiving results. In such a case, contact emergency services immediately or call our urgent genetic counselling line at +971 54 548 8731.
Patient FAQ & Clinical Guidance
Q1. What is the RAD51C gene test and why is it important?
Snippet: This NGS test detects inherited mutations in RAD51C that confer a 20‑40% lifetime ovarian and elevated breast cancer risk, enabling tailored prevention.
يكشف هذا الاختبار عن الطفرات الوراثية في جين RAD51C المرتبطة بارتفاع خطر الإصابة بسرطان المبيض والثدي مدى الحياة، مما يسمح بخطط وقائية دقيقة.
Pre‑test genetic counselling and pedigree analysis are mandatory to contextualise results.
Q2. How accurate is the test and what is the turnaround time?
Snippet: The assay achieves 99.9% analytical sensitivity using NGS with Sanger validation; final results are issued in 3–4 weeks.
تبلغ حساسية التحليل 99.9% باستخدام التسلسل الجيني المتقدم مع التحقق بطريقة سانجر، وتصدر النتائج خلال 3 إلى 4 أسابيع.
DNA can be extracted from a single drop of blood on an FTA card, whole blood, or extracted DNA.
Q3. Do I need a doctor’s referral or genetic counselling?
Snippet: Pre‑ genetic counselling is mandatory per UAE Federal Decree‑Law No. 41 of 2024 Art. 87 to ensure informed consent and proper risk assessment.
الاستشارة الوراثية قبل الاختبار إلزامية بموجب المرسوم بقانون اتحادي رقم 41 لعام 2024 المادة 87 لضمان الموافقة المستنيرة وتقييم المخاطر السليم.
A detailed family pedigree will be drawn during the counselling session; you can then proceed with the blood draw at our facility or via home collection.
Compliance: Federal Decree‑Law No. 41 of 2024 (Art. 87, Genetic Testing); UAE Consumer Data Protection Law (PDPL); CDS Law 2026 (Minors) – strict age‑verification protocols applied.
Accreditation: ISO 9001:2015 Quality Management System (Cert: INT/EGQ/2509DA/3139). Facility Licence: 9834453. Laboratory processing follows ACMG 2026 guidelines.
Methodology & Codes: Next‑Generation Sequencing (NGS) · ICD‑10‑CM 2026: Z15.01, Z15.02, Z14.01 · LOINC 94755-5.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians